BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced it has established a strategic partnership with Symbiance Inc., a specialty contract research organization (CRO) based in Princeton Junction, New Jersey. Symbiance concentrates in therapeutic areas relevant to pharmaceutical and biotechnology companies with particular focus in oncology and CNS.
“With their therapeutic expertise and knowledge of the clinical trial space, Symbiance is an excellent partner for BioClinica’s offerings. I am confident in the added value this partnership will bring to our mutual clients,” said Peter Benton, President of eClinical Solutions for BioClinica.
Symbiance began operations in 1990 to provide clear, precise and timely solutions for the data needs of clinical trial professionals. As a leading contract research organization with proven expertise in delivering innovative data solutions for pharmaceutical and biotechnology companies, Symbiance is committed to innovative and precise results that will allow clients to bring drugs to market quickly, accurately and cost effectively. Symbiance includes a clinical data management unit, biostatistical analysis, and SAS programming divisions supporting Phase I through IV clinical trials. For more information, please visit www.symbiance.com.
“The BioClinica Certified Partner Program saw significant growth in 2010,” continued Benton. “This growth has continued into the new year with the addition of experienced partners like Symbiance, allowing BioClinica to offer both a best in class product suite and added-value services for our clients. As many CROs seek partners that offer the highest level of technical expertise with global reach and support, they are finding that BioClinica fulfills their needs with the flexibility and capabilities that they require.”
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.